Table 2.

Associations with incident detection of aspartate aminotransferase to platelet ratio elevation.

Variable	Univariate OR (95% CI)	Multivariate ORa (95% CI)
Race/ethnicity
Caucasian	Reference	–
African-American	1.95 (0.56–6.85)
Hispanic	1.38 (0.31–6.07)
Other	NA
Age (years)	1.01 (0.95–1.07)	1.02 (0.95–1.09)
Body mass index (kg/m2)
Underweight (< 18.5)	–	–
Normal (18.5–25.0)	Reference
Overweight (> 25.0–30.0)	0.45 (0.16–1.27)
Obese (> 30.0)	1.04 (0.42–2.57)
Injection drug use
Current	1.49 (0.28–8.06)	–
Former	2.77 (0.63–12.24)
Never	Reference
Alcohol consumption
Light or abstains	Reference	Reference
Moderate or heavy	3.55 (1.52–8.30)**	3.38 (1.36–8.44)**
Liver toxic medicationsb
No	0.74 (0.34–1.60)	–
Yes	Reference
CD4 T-cell count (per 100 cells/ml)	1.11 (0.99–1.22)	0.82 (0.61–1.11)
HIV-RNA level (copies/ml)
< 4000	Reference	-
4001–20 000	2.07 (0.80–5.34)
20 001–100 000	0.92 (0.29–2.94)
> 100 000	1.05 (0.33–3.38)
Clinical AIDS at baseline
No AIDS	Reference
AIDS	0.94 (0.43–2.06)	–
IGFBP-3 (‘quartile’)b		Ptrend = 0.04
Q1	Reference	Reference
Q2	0.34 (0.12–0.98)*	0.23 (0.07–0.80)*
Q3	0.44 (0.15–1.26)	0.26 (0.07–1.04)
Q4	0.48 (0.15–1.53)	0.13 (0.02–0.76)*
IGF-I (‘quartile’)b		Ptrend = 0.03
Q1	Reference	Reference
Q2	0.73 (0.26–2.06)	0.97 (0.31–2.99)
Q3	0.99 (0.37–2.70)	1.32 (0.35–4.92)
Q4	1.64 (0.55–4.67)	5.83 (1.17–29.1)*

CI, Confidence interval; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; OR, odds ratio.

^*P < 0.05

^**P < 0.01

***P < 0.001

NA, not analysed.

^aMultivariate analyses conditioned on CD4 T-cell stratum (i.e. CD4 T cells < 200, 200–500, > 500 per ml) by stratification within each model, and also included the absolute value of CD4 T-cell count as a variable (to control for the exact CD4 T-cell level within each stratum); a weighted average was used to determine the effect estimate for each parameter.

^bSee details in Table 1.